Drugs in this class substantially increase HDL ("good cholesterol"), lower LDL ("bad cholesterol"), and enhance reverse cholesterol transport.<unk> s inhibit cholesterylester transfer protein <unk> , which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels and reduces LDL levels.<unk> s do not reduce rates of mortality, heart attack, or stroke in patients already taking a statin.
CETP inhibitor
Exopeptidase inhibitor
Xanthine oxidase inhibitor
Topoisomerase inhibitor
Protease inhibitor 
Endopeptidase inhibitor
Protein kinase inhibitor
Lipase inhibitors